Scope and Claims Analysis for US Patent 7,300,669: Fluticasone Propionate Topical Lotion with Vasoconstriction Advantage (Mineral Oil/White Soft Paraffin-Free)

US Drug Patent 7,300,669 is directed to a specific topical fluticasone formulation and a corresponding therapeutic method. The core claim scope is constrained by (i) tight wt.% ranges for fluticasone (or fluticasone salt/ester), (ii) a defined lipid alcohol base system (C14–C20 fatty alcohol, exemplified as cetostearyl alcohol), (iii) a defined skin conditioning agent (exemplified as isopropyl myristate), (iv) a defined humectant level (propylene glycol), (v) optional dimethicone and optional surfactants (with specific surfactant exemplification), and (vi) an explicit product limitation: the lotion is free of mineral oil and white soft paraffin. The claims also include an in-use performance surrogate: the lotion produces more vasoconstriction on living human skin than a comparator cream containing mineral oil or white soft paraffin, with the same fluticasone dose.

What is US Patent 7,300,669 and what does it claim?

Answer (scope in one line): The patent claims a mineral oil/white soft paraffin-free topical lotion formulation containing fluticasone (propionate in dependent claims) plus a defined base of cetostearyl alcohol (C14–C20 fatty alcohol), isopropyl myristate, propylene glycol, and optional dimethicone/surfactant, along with a method-of-treating fluticasone-responsive skin conditions by applying the lotion.

Claim set overview (based on provided claim text)

Claim	Type	Key limitations (high-level)	Mandatory?
1	Product	Fluticasone wt.%; C14–C20 fatty alcohol 4–6%; skin conditioning agent 1–5%; propylene glycol 5–15%; water balance; free of mineral oil and white soft paraffin; performance: more vasoconstriction vs same-dose cream with mineral oil/white soft paraffin	Yes
2	Product dependent	Adds surfactant 0.25–3%	Optional via dependency
3	Product dependent	Adds surfactant 0.5–2%	Optional via dependency
4	Product dependent	Adds dimethicone up to 5%	Optional via dependency
5	Product dependent	Dimethicone 0.5–3%	Optional via dependency
6	Product dependent	Dimethicone 1–2%	Optional via dependency
7	Product dependent	C14–C20 fatty alcohol = cetostearyl alcohol	Optional via dependency
8	Product dependent	Skin conditioning agent = isopropyl myristate	Optional via dependency
9	Product dependent	Adds surfactant 0.25–3% (when claim 8 applies)	Optional via dependency
10	Product dependent	Adds surfactant 0.5–2% (when claim 8 applies)	Optional via dependency
11	Product dependent	Surfactant = cetomacrogol	Optional via dependency
12	Product dependent	Adds one or more buffers	Optional via dependency
13	Product dependent	Adds one or more preservatives	Optional via dependency
14	Product dependent	Fluticasone = fluticasone propionate	Optional via dependency
15	Product dependent	Buffer = sodium citrate and/or citric acid	Optional via dependency
16	Product dependent	Preservative = imidurea; methylparaben; propylparaben	Optional via dependency
17	Method	Treat fluticasone-treatable skin condition by topical administration of lotion of claim 14	Yes if asserting method
18	Method dependent	Enumerated conditions (corticosteroid-responsive dermatosis, atopic dermatitis, inflammation, eczema, erythema, papulation, scaling, erosion, oozing, crusting, pruritis)	Yes if asserting claim 18
19	Product	A narrower “specific formulation” pack: 0.05% fluticasone propionate; cetostearyl alcohol 4–6%; isopropyl myristate 1–2%; propylene glycol 5–15%; dimethicone 0.5–3%; surfactant 0.25–3%; balance water; mineral oil/white soft paraffin-free; vasoconstriction advantage vs comparator	Yes (as written)

How do the claim ranges and exclusions define the formulation boundary?

1) Active: fluticasone wt.% (and the “salt or ester” hook)

Claim 1: 0.005 to 1.0 wt.% fluticasone or pharmaceutically acceptable salt/ester.
Claim 14 (dependent): fluticasone propionate.
Claim 19 (independent product): 0.05 wt.% fluticasone.

Practical effect: The patent covers broad fluticasone loading in the base claim, but in enforcement the most valuable hooks are typically the dependent claims that lock to fluticasone propionate and to specific formulation archetypes (claims 14 and 19).

2) Lipid alcohol: C14–C20 fatty alcohol

Claim 1: 4.0 to 6.0 wt.% of a C14–C20 fatty alcohol (or mixtures).
Claim 7: cetostearyl alcohol.

Practical effect: This confines the base to a narrow lipid-alcohol class and a tight wt.% window. A competitor swapping to other fatty alcohols outside C14–C20 (or materially changing the wt.%) can exit the claim even if the overall emulsion “feels similar.”

3) Skin conditioning agent: first skin conditioning agent

Claim 1: 1.0 to 5.0 wt.% of at least one first skin conditioning agent.
Claim 8: isopropyl myristate.

Practical effect: Many topical platforms use other emollients/esters; substitution away from the claimed class (as construed) and/or moving wt.% outside range is a straightforward design-around lever.

4) Humectant: propylene glycol

Claim 1 and claim 19: 5.0 to 15.0 wt.%.

Practical effect: Propylene glycol is not just a filler. Its wt.% anchors the formulation. Moving to glycerin, butylene glycol, or a different wt.% balance can reduce infringement risk.

5) Optional silicone: dimethicone

Claim 4: up to 5%.
Claim 5: 0.5–3%.
Claim 6: 1.0–2%.
Claim 19: 0.5–3%.

Practical effect: Because dimethicone is optional in claim 1 via dependency, the claim’s presence/absence is a key triangulation point for competitor products. Claim 1 covers formulations without dimethicone; therefore omitting dimethicone alone may not eliminate risk.

6) Optional surfactant: surfactant wt.% and specific example

Claim 2: 0.25–3%.
Claim 3: 0.5–2%.
Claim 11 (dependent): surfactant = cetomacrogol.
Claim 19: includes surfactant 0.25–3%.

Practical effect: Surfactant selection and wt.% matter for the dependent scope. But claim 1 already recites neither mandatory surfactant nor mandatory dimethicone. For infringement analysis, it is the comparator performance clause and the core excipient package that set the baseline.

7) Explicit excipient freedom: free of mineral oil and white soft paraffin

Claim 1 and claim 19: lotion is free of mineral oil and white soft paraffin.

Practical effect: This is a strong structural exclusion. If a competitor uses mineral oil and/or white soft paraffin, it is unlikely to meet the “free of” limitation as written, even if other ingredients align.

8) Performance limitation: more vasoconstriction than comparator cream

Claim 1 and claim 19: lotion causes more vasoconstriction on living human skin than does a cream containing mineral oil or soft white paraffin (or both) with the same amount of fluticasone.

Practical effect: This is the most litigation-sensitive language. It turns the claim into a performance-defined invention. In practice, the patentee can argue that even if ingredient ranges are met, the competitor’s product must demonstrate the claimed “more vasoconstriction” relative to the specified comparator.

What is the functional comparator and how does it narrow claim interpretation?

The claim’s comparator is not generic. It is a cream that:

contains mineral oil and/or white soft paraffin, and
contains the same amount of fluticasone as the accused lotion, and
is assessed via vasoconstriction when applied to living human skin.

Enforcement implication: Infringement and validity fights often hinge on how courts construe:

what “cream containing mineral oil or soft white paraffin” precisely means (composition, vehicle similarity, and whether the “same amount of fluticasone” controls),
what vasoconstriction assay is used,
and what degree of “more” is required (threshold, statistical significance, and test conditions).

The presence of a performance clause can also support patentability arguments that distinguish the claimed vehicle system over mineral-oil and petrolatum-like vehicles.

Which dependent claims create the tightest commercially actionable coverage?

The tightest anchors are:

Claim 7 (cetostearyl alcohol): constrains fatty alcohol identity.
Claim 8 (isopropyl myristate): constrains the ester/conditioning agent identity.
Claim 11 (cetomacrogol surfactant): constrains surfactant identity.
Claim 14 (fluticasone propionate): constrains active to the commercial steroid.
Claim 15 (sodium citrate and citric acid buffers) and Claim 16 (imidurea/methylparaben/propylparaben preservatives): constrain formulation auxiliaries.
Claim 19: provides a specific quantitative blueprint.

Commercial takeaway: If a product matches claim 19 exactly or closely, the infringement surface is smaller for both ingredient substitution and performance rebuttal.

What method-of-use claim coverage exists and how broad is it?

Claim 17 (method)

A method of treating skin conditions treatable by fluticasone by topical administration of the claim 14 lotion (fluticasone propionate formulation).

Claim 18 (method dependent)

Specifies:

corticosteroid-responsive dermatosis
atopic dermatitis
inflammation
eczema
erythema
papulation
scaling
erosion
oozing
crusting
pruritis

Interpretive effect: The “treatable by fluticasone” phrasing is broad at the therapeutic category level. The dependent enumeration can help tether claim construction to recognized corticosteroid-responsive disease states and symptoms, limiting arguments that the method is restricted to a narrow formulation of disease.

What patent landscape risks exist for generic or reformulated fluticasone lotions?

Key infringement pathways

A generic or reformulated topical product can face exposure if it:

stays within claim 1’s wt.% ranges for the core composition elements (fluticasone 0.005–1.0%; C14–C20 fatty alcohol 4–6%; skin conditioning agent 1–5%; propylene glycol 5–15%),
is free of mineral oil and white soft paraffin, and
can be asserted to have “more vasoconstriction” performance versus the specified mineral-oil/white-paraffin comparator cream.

Key design-around pathways

The strongest stated levers in the claim text:

Use mineral oil and/or white soft paraffin (break the “free of” limitation).
Move fatty alcohol identity or wt.% outside C14–C20 and/or outside 4–6%.
Change skin conditioning agent identity (leave the claimed category or move outside 1–5%).
Change propylene glycol wt.% outside 5–15% or substitute with different humectant design.
Change performance relative to the comparator (harder, because it is tied to vasoconstriction results rather than only ingredients).

Because claim 1 is a product claim with a performance dimension, a competitor can still be pulled in if it matches ingredients but not performance, depending on the strength of test evidence and claim construction.

How would an Orange Book/ANDA (or 505(b)(2)) regulatory route interact with this patent type?

This patent is a topical formulation + performance product patent and a method-of-treatment claim. In the US regulatory framework, such patents are often listed in the FDA Orange Book if tied to a particular drug product (application/strength/dosage form). The practical effect for challengers is:

Paragraph IV certifications (if applicable) focus on whether the listed patents are invalid, unenforceable, or not infringed.
For formulation patents, ANDA applicants can attempt design-around by changing excipients. But here the “free of mineral oil/white soft paraffin” and vasoconstriction clause constrain easy swapping.

Commercial decision risk: An ANDA or 505(b)(2) pathway can face longer timelines if the patent is listed and an NCE/combination isn’t required. Litigation can also force settlement or workarounds.

(No Orange Book listing details are included here because the question provides only claim text, not the Orange Book entry, patent publication date, or FDA application number.)

What does the claims text imply about priority/term and enforcement timing?

The patent number indicates a US grant: US 7,300,669. Term for granted US utility patents is generally measured from the earliest effective nonprovisional filing date with possible adjustments. The claim text alone does not provide:

priority filing date,
whether there were terminal disclaimers,
PTA,
or expiration date.

Accordingly, the enforceability window cannot be precisely mapped from the claims text alone.

How strong is the patent estate around this formulation concept?

Strength factors apparent from claim construction

Specificity in excipient identity and wt.% for multiple components (fatty alcohol class, conditioning agent, propylene glycol).
Hard negative limitation (free of mineral oil and white soft paraffin).
Performance feature (more vasoconstriction vs comparator cream with mineral oil/white soft paraffin).

Strength factors that can cut both ways

Performance clauses can create evidentiary burdens and become focal points for non-infringement arguments if the competitor’s product test results differ.
If the comparator cream and assay method are disputed, litigation may narrow to technical and statistical issues.

Enforcement-relevant claim hierarchy

Claim 1 is broad on active dose and allows optional surfactant/dimethicone.
Dependent claims funnel into more specific embodiments (cetostearyl alcohol, isopropyl myristate, cetomacrogol, specific preservatives/buffers).
Claim 19 offers a “center of mass” formulation snapshot useful for direct infringement proof.

What generic entry risks exist for fluticasone topical lotions?

High risk if the product looks like the claim family

Risk concentrates where a competitor:

uses fluticasone propionate with mineral-oil/white-paraffin-free lotion vehicles,
uses cetostearyl alcohol plus isopropyl myristate and propylene glycol in similar wt.%,
includes dimethicone and surfactants within claimed wt.%,
and achieves comparable vasoconstriction performance.

Lower risk via direct claim “breakers”

Lower risk arises when a competitor:

uses mineral oil and/or white soft paraffin (breaks claim language),
substitutes key excipients (fatty alcohol/conditioning agent) or shifts wt.%,
or changes humectant system away from propylene glycol within claimed window.

How does US 7,300,669 compare with typical fluticasone topical patent patterns?

Typical fluticasone topical IP estates include:

active ingredient use patents,
composition patents with broad excipient ranges,
and sometimes device or delivery system patents.

US 7,300,669 differs by:

anchoring on a mineral oil/white soft paraffin exclusion and
requiring vasoconstriction advantage over a defined comparator cream.

This makes the patent less about generic equivalence of vehicle viscosity or spreadability and more about a measurable pharmacodynamic proxy.

Timeline: what must be true for infringement or challenge to succeed?

Because the question does not provide:

filing dates,
patent expiration dates,
Orange Book listing details,
ANDA/505(b)(2) regulatory milestones,
or litigation records,

a complete timeline cannot be constructed without additional facts. The claims text supports the following litigation logic timeline instead:

Claim mapping: compare accused product’s wt.% and ingredient identity to claim 1/19 limits, including “free of mineral oil and white soft paraffin.”
Comparator construction: define the specified mineral-oil/white-paraffin comparator cream with same fluticasone dose.
Vasoconstriction testing: establish assay, conditions, and statistical evaluation showing “more vasoconstriction.”
Non-infringement defenses: argue excipient outside range/identity, mineral oil/white paraffin presence, missing performance advantage, or assay mismatch.
Validity challenges: likely target novelty/obviousness of the vehicle system and performance clause sufficiency, depending on the prior art record.

Key Takeaways

US 7,300,669 claims a mineral oil and white soft paraffin-free topical lotion with fluticasone and a tightly defined vehicle: C14–C20 fatty alcohol (4–6%), skin conditioning agent (1–5%), propylene glycol (5–15%), and water balance.
Claim 1 includes an explicit performance limitation: the lotion must cause more vasoconstriction on living human skin than a mineral-oil/white-soft-paraffin cream with the same fluticasone dose.
Dependent claims narrow the scope to fluticasone propionate (claim 14), cetostearyl alcohol (claim 7), isopropyl myristate (claim 8), cetomacrogol surfactant (claim 11), and specific buffers/preservatives (claims 15–16).
Claim 19 provides a commercially specific formulation embodiment that can be directly compared to a competitor’s ingredient sheet.
For generic or reformulated entrants, the most direct claim “breakers” are adding mineral oil/white soft paraffin, moving key excipients outside identity/wt.% windows, or failing to reproduce the claimed vasoconstriction advantage relative to the specified comparator.

FAQs

What ingredient substitutions are most likely to avoid infringing US 7,300,669?
Changing the fatty alcohol identity/level (C14–C20; 4–6%), the skin conditioning agent identity/level (1–5%), propylene glycol level (5–15%), or adding mineral oil/white soft paraffin.
Does US 7,300,669 require dimethicone to infringe?
No. Dimethicone is optional in the dependent claim set; claim 1 covers lotions without it.
Is “more vasoconstriction” an ingredient-only test or a formulation-performance requirement?
It is a formulation-performance requirement tied to a defined comparator cream and measured on living human skin.
Which claims most directly cover a fluticasone propionate topical lotion product?
Claim 14 (fluticasone propionate) and the independent embodiment in claim 19 (0.05 wt.% fluticasone with defined excipient ranges).
What therapeutic indications are covered by the method claims?
Claim 18 enumerates corticosteroid-responsive dermatoses including atopic dermatitis, eczema, erythema, pruritis, and other inflammatory skin manifestations.

References

(No external sources were provided in the prompt. Only the claim text supplied by the user is used here.)

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	6352499	⤷ Start Trial
Australia	754480	⤷ Start Trial
Brazil	9914703	⤷ Start Trial
Canada	2347109	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,300,669

Summary for Patent: 7,300,669